Zomedica ZOMDF
OTC ZOMDF
$0.08 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Zomedica (ZOMDF) Return on Sales [ROS] (2021 - 2026)

Updated

Zomedica's Return on Sales [ROS] was -42.92% in Q2 2026, up 72.45 percentage points from -115.38% a year earlier and up 12.76 percentage points from the prior quarter.

Analysis

Zomedica (ZOMDF) Return on Sales [ROS] (2021 - 2026) Analysis & Trends

On a trailing twelve-month basis, Zomedica's Return on Sales [ROS] was -56.28% through Jun 30, 2026, up 254.71 percentage points year-over-year; for FY2025, it came in at -263.36%, down 76.25 percentage points from FY2024.

  • Return on Sales [ROS] has now declined for three consecutive years, though with a four-year change of +253.80 percentage points (FY2021 to FY2025).
  • In earlier years, Return on Sales [ROS] was -187.11% in FY2024 (-15.29 pp), -171.82% in FY2023 (-56.01 pp), -115.81% in FY2022 (+401.34 pp) and -517.15% in FY2021.
  • The Q2 2026 figure marks the highest quarterly Return on Sales [ROS] in data going back to Q1 2021.
  • Compared with a year earlier, Return on Sales [ROS] has increased for five straight quarters, with an average year-over-year change of +94.17 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Sales [ROS] over five years was Q2 2022 (a gain of 33167.77 percentage points); the worst was Q1 2025 (a drop of 827.19 percentage points).
  • Per Business Quant data, ZOMDF's Return on Sales [ROS] in the three quarters before Q2 2026 was -55.69% (Q1 2026), -49.32% (Q4 2025) and -81.61% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Zomedica 78.40 Mn -119.63 Mn 6.04 Mn -42.92%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -42.92%
Mar 31, 2026 -55.69%
Dec 31, 2025 -49.32%
Sep 30, 2025 -81.61%
Jun 30, 2025 -115.38%
Mar 31, 2025 -993.05%
Dec 31, 2024 -103.36%
Sep 30, 2024 -106.33%
Jun 30, 2024 -408.86%
Mar 31, 2024 -165.86%
Dec 31, 2023 -314.46%
Sep 30, 2023 -93.71%
Jun 30, 2023 -111.99%
Mar 31, 2023 -137.03%
Dec 31, 2022 -83.42%
Sep 30, 2022 -138.02%
Jun 30, 2022 -138.48%
Mar 31, 2022 -115.01%
Dec 31, 2021 -141.26%
Sep 30, 2021 -27,860.87%
API Access

Zomedica Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=ZOMDF&period=max&api_key=YOUR_API_KEY